| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.35 | 6e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0005 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0009 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.14 | 0.001 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |